ライフサイエンスコーパス: pemetrexed

1 50 = 120 nM, about 55-fold more potent than pemetrexed).

2 vival outcomes as compared with single-agent pemetrexed.

3 ms that predict for survival and toxicity of pemetrexed.

4 d cisplatin and pemetrexed or paclitaxel and pemetrexed.

5 he transport and pharmacological activity of pemetrexed.

6 ures predicting sensitivity to cisplatin and pemetrexed.

7 ven patients were treated with 167 cycles of pemetrexed.

8 ears (range, 47 to 75 years) for carboplatin/pemetrexed.

9 %; P <.001) compared with patients receiving pemetrexed.

10 ion of apricoxib to second-line docetaxel or pemetrexed.

11 of ADI-PEG20 activity by the antifolate drug pemetrexed.

12 These cells were cross-resistant to pemetrexed.

13 received gemcitabine, and 497 (33%) received pemetrexed.

14 95% CI, 0.64 to 0.96; P = .0195; median OS: pemetrexed, 13.9 months; placebo, 11.0 months).

15 ss frequent in elderly patients treated with pemetrexed (2.5%) compared with docetaxel (19%; P = .025

16 Of the remaining 938 patients, 605 received pemetrexed (301 patients with cetuximab and 304 alone) a

17 ment occurred along with a rapid adoption of pemetrexed (39.2%), erlotinib (20.3%), and bevacizumab (

18 y of carboplatin area under the curve 5 with pemetrexed 500 mg/m(2) administered intravenously on day

19 2), 27 mg/m(2), or 36 mg/m(2), together with pemetrexed 500 mg/m(2) and cisplatin 75 mg/m(2) which we

20 ed seventy-one patients received intravenous pemetrexed 500 mg/m(2) day 1 and oral ABT-751 or placebo

21 oplatin area under curve 5 mg/mL per min and pemetrexed 500 mg/m(2) every 3 weeks followed by pembrol

22 Patients received pemetrexed 500 mg/m(2) intravenously (i.v.) day 1 with v

23 nts received either cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 of a 3-week cycle for a

24 citabine 1,250 mg/m(2) on days 1 and 8, with pemetrexed 500 mg/m(2) on day 1.

25 citabine 1,250 mg/m(2) on days 1 and 8, with pemetrexed 500 mg/m(2) on day 8, and cohort 2 received g

26 ublet chemotherapy cisplatin 75 mg/m(2) plus pemetrexed 500 mg/m(2) on the first day of each cycle.

27 Docetaxel 75 mg/m(2) or pemetrexed 500 mg/m(2) once every 21 days per the invest

28 umab 7.5 mg/kg or bevacizumab 7.5 mg/kg plus pemetrexed 500 mg/m(2) once every 3 weeks until disease

29 eatment cycles) or chemotherapy (intravenous pemetrexed 500 mg/m(2) or docetaxel 75 mg/m(2) [investig

30 of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combine

31 Patients received pemetrexed 500 mg/m(2) plus cisplatin 75 mg/m(2) for fou

32 otinib (150 mg/day, orally) or chemotherapy (pemetrexed 500 mg/m(2), intravenously, every 21 days, or

33 ) plus three-weekly cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2).

34 latin 75 mg/m(2) or carboplatin AUC 5-6 plus pemetrexed 500 mg/m(2)] every 3 weeks for four cycles fo

35 ve surgery were randomly assigned to receive pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1, or

36 s randomly assigned to docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 every 3 weeks were analyzed for eff

37 Patients received pemetrexed 500 mg/m2 intravenously on day 1 every 21 day

38 Patients were randomly assigned to receive pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or pemetrex

39 were randomly assigned to three schedules of pemetrexed 500 mg/m2 plus gemcitabine 1,250 mg/m2, separ

40 aily or intravenous chemotherapy with either pemetrexed (500 mg per square meter of body-surface area

41 ock and Simon minimisation method to receive pemetrexed (500 mg/m(2) every 21 days; n=441) or placebo

42 were randomly assigned (2:1) to maintenance pemetrexed (500 mg/m(2) on day 1 of 21-day cycles; n = 3

43 mcitabine (1200 mg/m(2) on days 1 and 8), or pemetrexed (500 mg/m(2) on day 1).

44 ression, patients in all three arms received pemetrexed (500 mg/m(2) once every 21 days) as predefine

45 nts were randomly assigned to receive either pemetrexed (500 mg/m(2)) or docetaxel (75 mg/m(2)) and t

46 With vitamin supplementation, pemetrexed 600 mg/m2 was tolerated by patients with a GF

47 Postdiscontinuation therapy use was similar: pemetrexed, 64%; placebo, 72%.

48 After 397 deaths (pemetrexed, 71%; placebo, 78%) and a median follow-up of

49 b and 116 (50%) to chemotherapy (40 [34%] to pemetrexed, 73 [63%] to docetaxel, and three [3%] discon

50 ctor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell

51 n tumors, and the ability of PCFT to sustain pemetrexed activity even in the absence of RFC, tumor ce

52 CFT and RFC produced comparable increases in pemetrexed activity in growth medium with 5-formyltetrah

53 We suggest that the activity of pemetrexed against human cancers is a reflection of its

54 Pemetrexed (ALIMTA, Lilly) is a folate antimetabolite th

55 ce therapy or to 4 cycles of carboplatin and pemetrexed alone followed by indefinite pemetrexed maint

56 ith five (2%) of 289 treated patients in the pemetrexed alone group.

57 reased neutrophil count (28 [10%]), and with pemetrexed alone were dyspnoea (35 [12%] of 289 patients

58 t to require AMPKalpha T172 phosphorylation, pemetrexed also activated AMPK in carcinoma cells null f

59 with three clinically prevalent antifolates, pemetrexed (also Alimta), aminopterin, and methotrexate.

60 The chemotherapeutic drug pemetrexed, an inhibitor of thymidylate synthase, has an

61 stent with FR-mediated transport, subsequent pemetrexed and (6S)-5-formyltetrahydrofolate export into

62 enance cycles was 7.9 (range, one to 44) for pemetrexed and 5.0 (range, one to 38) for placebo.

63 years (range, 46 to 82 years) for cisplatin/pemetrexed and 66 years (range, 47 to 75 years) for carb

64 tin, and bevacizumab followed by maintenance pemetrexed and bevacizumab in patients with chemotherapy

65 or patients with response or stable disease, pemetrexed and bevacizumab were continued until disease

66 bocytopenia (13.2% v 22.9%) in the cisplatin/pemetrexed and carboplatin/pemetrexed treatment groups,

67 patients to receive either necitumumab plus pemetrexed and cisplatin (n=315) or pemetrexed and cispl

68 mab plus pemetrexed and cisplatin (n=315) or pemetrexed and cisplatin alone (n=318).

69 ] of 304 vs one [<1%] of 312 patients in the pemetrexed and cisplatin alone group), hypomagnesaemia (

70 ] vs 11 [4%] patients) than did those in the pemetrexed and cisplatin alone group.

71 citumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previous

72 The median number of pemetrexed and cisplatin cycles was six; the median trea

73 oves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of pat

74 s pemetrexed and cisplatin group than in the pemetrexed and cisplatin group (155 [51%] of 304 vs 127

75 group versus 11.5 months (10.1-13.1) in the pemetrexed and cisplatin group (hazard ratio 1.01 [95% C

76 Patients in the necitumumab plus pemetrexed and cisplatin group had more grade 3-4 rash (

77 kewise more frequent in the necitumumab plus pemetrexed and cisplatin group than in the pemetrexed an

78 g deaths, was higher in the necitumumab plus pemetrexed and cisplatin group than in the pemetrexed an

79 hs (95% CI 9.5-13.4) in the necitumumab plus pemetrexed and cisplatin group versus 11.5 months (10.1-

80 roup versus nine (3%) of 312 patients in the pemetrexed and cisplatin group.

81 s pemetrexed and cisplatin group than in the pemetrexed and cisplatin group; in particular, deaths re

82 suggest that the addition of necitumumab to pemetrexed and cisplatin increases survival of previousl

83 signed in a 1:1 ratio to up to six cycles of pemetrexed and cisplatin plus nintedanib (200 mg twice d

84 II trial to determine whether treatment with pemetrexed and cisplatin results in survival time superi

85 We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin a

86 of 456 patients were assigned: 226 received pemetrexed and cisplatin, 222 received cisplatin alone,

87 n this patient population when combined with pemetrexed and cisplatin.

88 and 8.8% (analysis of variance P =.105) for pemetrexed and docetaxel, respectively.

89 versus 7.9 months (P = not significant) for pemetrexed and docetaxel, respectively.

90 , switch maintenance therapy strategies with pemetrexed and erlotinib have demonstrated improved over

91 Pemetrexed and gemcitabine administered as outlined for

92 Pemetrexed and gemcitabine are synergistic in preclinica

93 Pemetrexed and gemcitabine have single-agent activity in

94 luate the optimum administration schedule of pemetrexed and gemcitabine in chemotherapy-naive patient

95 rongly suggest that combination therapy with pemetrexed and gemcitabine is a promising treatment for

96 We found that pemetrexed and gemcitabine preferentially inhibited G3 M

97 The combination of pemetrexed and gemcitabine resulted in moderate clinical

98 times are similar to those with single-agent pemetrexed and inferior to outcomes observed with cispla

99 Thymidylate synthase (TS) is a target for pemetrexed and the prodrug 5-fluorouracil (5-FU) that in

100 erstand the role of autophagy in response to pemetrexed and to test if combination therapy could enha

101 nt to which PCFT contributes to transport of pemetrexed and to the activities of this and other antif

102 50 = 46 nM, about 206-fold more potent than pemetrexed) and DHFR (IC 50 = 120 nM, about 55-fold more

103 rapy; 22 of 39 second-line patients received pemetrexed, and nine of 39 received erlotinib.

104 Pemetrexed, approved for the treatment of non-small cell

105 gnificantly improved in the bevacizumab plus pemetrexed arm (median, 3.7 v 7.4 months; hazard ratio,

106 motherapy, were randomly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B

107 or cells are unlikely to become resistant to pemetrexed as a result of impaired transport because of

108 ranslation and lipid metabolism, identifying pemetrexed as a targeted therapeutic agent for this path

109 anistic rationale for combining GMX1777 with pemetrexed as an effective new therapeutic strategy to t

110 s in both arms received up to four cycles of pemetrexed as consolidation therapy.

111 and efficacy of bevacizumab with or without pemetrexed as continuation maintenance treatment.

112 Combination of Gli-I and pemetrexed, as well as Gli-I and vismodegib demonstrated

113 Pemetrexed at a dose of 900 mg/m(2) was to be administer

114 New compounds such as pemetrexed, bortezomib, TLK286, bevacizumab, and the epo

115 increased the growth inhibitory activity of pemetrexed, but not that of the other antifolates in Hep

116 omic predictors of response to cisplatin and pemetrexed can be incorporated into strategies to optimi

117 l studies indicate that the toxic effects of pemetrexed can be reduced by dietary folate, resulting i

118 PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With

119 s study evaluated the efficacy and safety of pemetrexed, carboplatin, and bevacizumab followed by mai

120 The combination of pemetrexed, carboplatin, and TRT met the prespecified cr

121 onse rates were also significantly lower for pemetrexed-carboplatin (31% v 52%; P < .001).

122 le between arms and anemia was higher in the pemetrexed-carboplatin arm.

123 Pemetrexed-carboplatin had lower grade 3 to 4 neutropeni

124 Pemetrexed-carboplatin is inferior for the treatment of

125 objective of the study was noninferiority of pemetrexed-carboplatin overall survival with a 15% margi

126 In the final analysis, pemetrexed-carboplatin was inferior to etoposide-carbopl

127 , a phase III study was conducted to compare pemetrexed-carboplatin with etoposide-carboplatin for th

128 /kg plus gemcitabine-cisplatin (squamous) or pemetrexed-cisplatin (nonsquamous) or nivolumab 5 or 10

129 1 ratio to receive afatinib or chemotherapy (pemetrexed-cisplatin [LUX-Lung 3] or gemcitabine-cisplat

130 nib group and 28.2 months (20.7-33.2) in the pemetrexed-cisplatin group (HR 0.88, 95% CI 0.66-1.17, p

131 rformance status who did not progress during pemetrexed-cisplatin induction therapy.

132 lung cancer (NSCLC) received four cycles of pemetrexed-cisplatin induction therapy; then, 539 patien

133 mcitabine-cisplatin, nivolumab 10 mg/kg plus pemetrexed-cisplatin, nivolumab 10 mg/kg plus paclitaxel

134 Response rates were 41.3% in the pemetrexed/cisplatin arm versus 16.7% in the control arm

135 he hazard ratio for death of patients in the pemetrexed/cisplatin arm versus those in the control arm

136 Median survival time in the pemetrexed/cisplatin arm was 12.1 months versus 9.3 mont

137 a significant reduction in toxicities in the pemetrexed/cisplatin arm.

138 progression was significantly longer in the pemetrexed/cisplatin arm: 5.7 months versus 3.9 months (

139 , the in vitro enzyme velocity at saturating pemetrexed concentrations was reduced by 1.6-fold (R424C

140 ith stable disease or response to first-line pemetrexed-containing regimens, alternative chemotherapy

141 Maintenance therapy includes pemetrexed continuation for patients with stable disease

142 Pemetrexed continuation maintenance therapy is well-tole

143 In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the

144 mbination of pembrolizumab, carboplatin, and pemetrexed could be an effective and tolerable first-lin

145 four standard-dose courses of cisplatin plus pemetrexed (CP).

146 overall survival seem comparable to that of pemetrexed, docetaxel, and erlotinib in similar groups o

147 hibited this effect, impairing cell death by pemetrexed either alone or in combination with GMX1777.

148 Twenty-six patients received pemetrexed (either alone or in combination with platinum

149 l, on a 21-day cycle as follows: schedule A, pemetrexed followed by gemcitabine on day 1 and gemcitab

150 8; and schedule C, gemcitabine on day 1 and pemetrexed followed by gemcitabine on day 8.

151 as determined by histology: carboplatin plus pemetrexed for nonsquamous NSCLC and carboplatin plus ge

152 include docetaxel, erlotinib, gefitinib, or pemetrexed for patients with nonsquamous cell carcinoma;

153 The combination of pemetrexed/gemcitabine has not previously been studied i

154 proportion of patients in the cetuximab plus pemetrexed group (119 [41%] of 292 patients) experienced

155 ous adverse event than those patients in the pemetrexed group (85 [29%] of 289 patients; p=0.0054).

156 n and 99.95% for pemetrexed in the cisplatin/pemetrexed group and 93.21% for carboplatin and 98.50% f

157 of 292 treated patients in the cetuximab and pemetrexed group died of adverse events compared with fi

158 greater increase in loss of appetite in the pemetrexed group than in the placebo group (4.3 mm vs 0.

159 and 98.50% for pemetrexed in the carboplatin/pemetrexed group.

160 ulted in substantial raltitrexed, but modest pemetrexed, growth inhibition consistent with their affi

161 ifolates (relative affinities: raltitrexed > pemetrexed > MTX) at low pH.

162 Elderly patients treated with pemetrexed had a longer time to progression and a longer

163 ents who received bevacizumab, erlotinib, or pemetrexed had the longest treatment durations on averag

164 Pemetrexed has more than one site of action; the primary

165 Pemetrexed has shown good activity in preclinical models

166 Pemetrexed has sufficient activity in the treatment of r

167 Switch-maintenance trials with erlotinib and pemetrexed have demonstrated an improvement in overall s

168 axel, erlotinib, gefitinib, gemcitabine, and pemetrexed have evaluated outcomes in patients who recei

169 Newer agents, such as pemetrexed, have shown significant activity as second-li

170 CI 2.7-3.2) versus 2.8 months (2.5-3.3) with pemetrexed (HR 1.03, 95% CI 0.87-1.21; p=0.76).

171 t improved by the addition of carboplatin to pemetrexed (HR, 90; 95% CI, 0.74 to 1.10; P = .316; P he

172 , pharmacokinetics, and recommended doses of pemetrexed in cancer patients with normal and impaired r

173 es (DLTs), and pharmacokinetic properties of pemetrexed in children.

174 Pemetrexed in combination with cisplatin demonstrates ac

175 Pemetrexed in combination with cisplatin is approved for

176 Hence, resistance to pemetrexed in M160-8 cells was due to entrapment of the

177 d tolerability of ADI-PEG 20, cisplatin, and pemetrexed in patients with ASS1-deficient malignant ple

178 ternative, single-agent chemotherapy such as pemetrexed in patients with nonsquamous histology, docet

179 oup analyses, the addition of carboplatin to pemetrexed in patients with squamous tumors led to a sta

180 ate the use of cisplatin or carboplatin plus pemetrexed in previously untreated ES-SCLC.

181 to assess the impact of carboplatin added to pemetrexed in terms of overall survival (OS).

182 up and 93.21% for carboplatin and 98.50% for pemetrexed in the carboplatin/pemetrexed group.

183 ose) was 98.94% for cisplatin and 99.95% for pemetrexed in the cisplatin/pemetrexed group and 93.21%

184 rexed susceptibility phenotype variation for pemetrexed in the discovery population.

185 othelial tissues and the differences between pemetrexed-induced senescence and that induced by the re

186 strate concentrations (~2.5 muM), only [(3)H]pemetrexed influx [in contrast to methotrexate (MTX), fo

187 The pemetrexed influx K(m) was ~300 muM; the raltitrexed inf

188 erized in detail in the NCI-H28 line, with a pemetrexed influx K(t) of 30 nM and V(max) of 10 nmol/g

189 At 300 muM MTX, influx was one-third that of pemetrexed; influx of folic acid, (6S)5-methyltetrahydro

190 AICART reaction, ZMP, accumulated in intact pemetrexed-inhibited tumor cells, identifying AICART as

191 ur findings indicate that AMPK activation by pemetrexed inhibits mTORC1-dependent and -independent pr

192 he recommended phase II dose of ABT-751 with pemetrexed is 200 mg.

193 Pemetrexed is a multitargeted antifolate with manageable

194 Pemetrexed is a novel antifolate that inhibits multiple

195 Carboplatin/pemetrexed is a well-tolerated regimen with activity in

196 Pemetrexed is an inhibitor of dihydrofolate reductase cu

197 Pemetrexed is known to activate PARPs, thereby accelerat

198 Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy.

199 mmended; in patients with nonsquamous NSCLC, pemetrexed is recommended.

200 eling of the licensed agents bevacizumab and pemetrexed is restricted to patients with nonsquamous ce

201 Single-agent pemetrexed is safe and active as second-line treatment o

202 lity of life during maintenance therapy with pemetrexed is similar to placebo, except for a small inc

203 Pemetrexed is well-tolerated in children with refractory

204 Addition of ABT-751 to pemetrexed is well-tolerated, but does not improve outco

205 a phase I trial and pharmacokinetic study of pemetrexed (LY231514) in children and adolescents with r

206 y pembrolizumab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carbopl

207 Pemetrexed maintenance therapy significantly improved ov

208 all and progression-free survival noted with pemetrexed maintenance therapy, such treatment is an opt

209 and pemetrexed alone followed by indefinite pemetrexed maintenance therapy.

210 motherapy plus bevacizumab, bevacizumab plus pemetrexed maintenance was associated with a significant

211 ts occurred more often with bevacizumab plus pemetrexed maintenance.

212 Antifolates currently in the clinic, such as pemetrexed, methotrexate, and pralatrexate, are transpor

213 l and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99

214 el and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11

215 nd 8.0 months for younger patients receiving pemetrexed (n = 236) or docetaxel (n = 249), respectivel

216 Elderly patients receiving pemetrexed (n = 47) or docetaxel (n = 39) had a median s

217 d whether the indirect activation of AMPK by pemetrexed offers an effective therapeutic strategy for

218 n day 8; schedule B, gemcitabine followed by pemetrexed on day 1 and gemcitabine on day 8; and schedu

219 rvival with cetuximab plus pemetrexed versus pemetrexed, on an intention-to-treat basis.

220 e, investigators chose whether to treat with pemetrexed or docetaxel on a patient-by-patient basis.

221 nonsquamous patients received cisplatin and pemetrexed or paclitaxel and pemetrexed.

222 ival (OS); patients who received second-line pemetrexed or with a performance status of 0 appeared to

223 zumab with either chemotherapy (docetaxel or pemetrexed) or erlotinib and preliminarily assessed thes

224 Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (

225 Pemetrexed plasma and urine pharmacokinetics were evalua

226 Pemetrexed plasma clearance positively correlated with G

227 Following a phase II trial in which pemetrexed-platinum demonstrated similar activity to tha

228 Given the activity and tolerability of pemetrexed/platinum combinations in non-small-cell lung

229 Pemetrexed/platinum doublets had activity and appeared t

230 eived maintenance until disease progression: pemetrexed plus bevacizumab (for the PemCBev group) or b

231 latin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (P

232 ly assigned to receive pemetrexed (arm A) or pemetrexed plus carboplatin (arm B).

233 etrexed 500 mg/m2 plus cisplatin 75 mg/m2 or pemetrexed plus carboplatin area under the concentration

234 Second-line treatment of advanced NSCLC with pemetrexed plus carboplatin does not improve survival ou

235 eived pemetrexed plus cisplatin, 18 received pemetrexed plus carboplatin, and four received a combina

236 Treatment with pemetrexed plus cisplatin and vitamin supplementation re

237 ed that trimodality therapy with neoadjuvant pemetrexed plus cisplatin is feasible with a reasonable

238 Conclusion Addition of nintedanib to pemetrexed plus cisplatin resulted in PFS improvement.

239 Neoadjuvant pemetrexed plus cisplatin was administered, followed by

240 A total of 26 patients received pemetrexed plus cisplatin, 18 received pemetrexed plus c

241 inical study assessed safety and efficacy of pemetrexed plus gemcitabine in chemotherapy-naive patien

242 The combination of pemetrexed plus gemcitabine was active in patients with

243 brids of the clinically used anticancer drug pemetrexed (PMX) and our 6-substituted thiopheneyl pyrro

244 Compound 2 and pemetrexed (Pmx) competed with [(3)H]methotrexate for PC

245 Both 1 and pemetrexed (Pmx) inhibited proliferation of R1-11-PCFT4

246 Pemetrexed (PMX) is a 5-substituted pyrrolo[2,3-d]pyrimi

247 e carrier (RFC) was only 2-fold resistant to pemetrexed (PMX), but 200- and 400-fold resistant to ral

248 Pemetrexed pretreatment inhibited biotinylation of TMD2

249 In this subset, pemetrexed produced a more favorable toxicity profile.

250 bition of purine synthesis by the antifolate pemetrexed (PTX), a drug used extensively in the treatme

251 eeks for four cycles followed by maintenance pemetrexed); randomisation was stratified by World Healt

252 While pemetrexed rapidly associated with FR and was internaliz

253 the IC(50) values for both methotrexate and pemetrexed relative to the WT Cyt form of FPGS.

254 Like rapamycin analogs, pemetrexed relieved feedback suppression of PI3K and AKT

255 Pemetrexed represents the first antifolate cancer drug t

256 tly, between the likelihood of cisplatin and pemetrexed response in patients.

257 y aimed at identifying genetic predictors of pemetrexed response.

258 Treatment with pemetrexed resulted in clinically equivalent efficacy ou

259 The addition of bevacizumab to pemetrexed resulted in promising efficacy outcomes in SC

260 Genomic-derived signatures of cisplatin and pemetrexed sensitivity were shown to accurately predict

261 tion was seen between in vitro cisplatin and pemetrexed sensitivity, and importantly, between the lik

262 and severe pulmonary hemorrhage, whereas for pemetrexed, superior treatment effects have been observe

263 ioblastoma, the combination of sorafenib and pemetrexed suppressed tumor growth without deleterious e

264 3 expression signature explained >30% of the pemetrexed susceptibility phenotype variation for pemetr

265 into the observed genetic associations with pemetrexed susceptibility.

266 f resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for

267 is (HR 0.58, 95% CI 0.34-0.97; p=0.038) with pemetrexed than with placebo; no other significant diffe

268 e so when used in combination with cisplatin+pemetrexed, the current standard of care.

269 n predictors of susceptibility phenotype for pemetrexed, the work presented here will be valuable to

270 live patients (95% CI, 23.2 to 25.1 months), pemetrexed therapy resulted in a statistically significa

271 cted in a greater than additive fashion with pemetrexed to increase autophagy and to kill a diverse a

272 glutamation of folic acid, methotrexate, and pemetrexed to produce highly active metabolites.

273 motherapeutic response to both cisplatin and pemetrexed to provide a rational approach to effective i

274 Polymorphisms in genes responsible for pemetrexed transport (reduced folate carrier [SLC19A1])

275 Activation of AMPK by ZMP in pemetrexed-treated colon and lung carcinoma cells and th

276 and neutropenia were significantly higher in pemetrexed-treated patients.

277 in the cisplatin/pemetrexed and carboplatin/pemetrexed treatment groups, respectively.

278 ounteracting the increase of OCT4 induced by pemetrexed treatment which is known to favor the develop

279 ingle-agent bevacizumab and bevacizumab plus pemetrexed treatment, respectively.

280 nogenicity, cell migration and resistance to pemetrexed treatment.

281 rogression-free survival with cetuximab plus pemetrexed versus pemetrexed, on an intention-to-treat b

282 CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) month

283 Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months

284 The MST for carboplatin/pemetrexed was 10.4 months, with a 1-year survivorship o

285 rogression-free survival with cetuximab plus pemetrexed was 2.9 months (95% CI 2.7-3.2) versus 2.8 mo

286 emetrexed was 4.9 months and for carboplatin/pemetrexed was 4.5 months.

287 Median time to progression for cisplatin/pemetrexed was 4.9 months and for carboplatin/pemetrexed

288 Median survival time (MST) for cisplatin/pemetrexed was 7.6 months, with a 1-year survivorship of

289 Pemetrexed was administered as a 10-minute intravenous i

290 Survival on pemetrexed was consistently improved for all patient sub

291 Recently, continuation maintenance with pemetrexed was found to prolong overall survival as well

292 Treatment with carboplatin plus pemetrexed was initiated, without bevacizumab because of

293 In addition, resistance to gemcitabine and pemetrexed was observed at the highest drug concentratio

294 Pemetrexed was well tolerated at doses of 500 mg/m2 with

295 es (median, four; range one to 19 cycles) of pemetrexed were administered, with 40% of patients recei

296 grade 3-4 adverse events with cetuximab plus pemetrexed were fatigue (33 [11%] of 292 patients), acne

297 nd randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recu

298 We found that combining pemetrexed with GMX1777 produced a synergistic therapeut

299 ally impaired patients receiving higher dose pemetrexed with vitamin supplementation.

300 t HepG2 cells, exhibited a high affinity for pemetrexed, with an influx K(m) value of 0.2 to 0.8 muM